Investigating the role of Circ0014614 in essential thrombocytosis
The Role of Circ0014614 in the Formation and Development of ET
This study is trying to see how a specific molecule called Circ0014614 affects people with essential thrombocytosis by looking at their bone marrow samples before and after treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years to 64 Years |
| Sex | All |
| Sponsor | Nanfang Hospital, Southern Medical University Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT05921838 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the role of Circ0014614 in the formation and development of essential thrombocytosis (ET). It will involve collecting bone marrow samples from ET patients to analyze the levels of Circ0014614 in both peripheral blood and bone marrow before and after treatment. The study will also utilize bioinformatics to predict the downstream microRNA and mRNA associated with Circ0014614, providing insights into its potential mechanisms in the disease's progression. The research seeks to better understand how mutated hematopoietic stem cells may influence the tumor microenvironment in myeloproliferative diseases.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have been diagnosed with essential thrombocytosis according to WHO criteria.
Not a fit: Patients who do not have a diagnosis of essential thrombocytosis or those deemed unsuitable by the researcher will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new insights into the mechanisms of essential thrombocytosis, potentially guiding future therapeutic strategies.
How similar studies have performed: While the specific role of Circ0014614 in ET is novel, similar studies investigating the tumor microenvironment in myeloproliferative diseases have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. According to the classification and diagnostic criteria of hematological myeloid tumors by WHO 2016, patients diagnosed as ET are standardized 2. Voluntary signing of informed consent form 3. Age ≥ 18 years old, regardless of gender 4. No pregnancy plan during treatment Exclusion Criteria: 1.The researcher judged that it was not suitable to participate in this study
Where this trial is running
Guangzhou, Guangdong
- Department of Hematology,Nanfang Hospital, Southern Medical University — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Principal investigator: Dan Xu — Nanfang Hospital, Southern Medical University
- Study coordinator: Dan Xu
- Email: 522111156@qq.com
- Phone: +86-20-61641615
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.